ThymoQuin® is TriNutra’s USP-grade, standardized black seed oil (Nigella sativa), clinically studied for cortisol regulation, stress resilience, sleep, and metabolic health. Below is ThymoQuin’s 2026 press and clinical coverage across leading nutrition and personal-care publications.
June 17, 2026
A new US patent recognizes ThymoQuin's synergistic activity with astaxanthin, potentiating its balanced inflammatory response - adding to ThymoQuin's growing portfolio of global patents covering composition, stability, and bioavailability.
Read the full article →
June 17, 2026
TriNutra's new US patent covers ThymoQuin combined with astaxanthin, with published research confirming synergistic biological activity that enhances anti-inflammatory and antioxidant efficacy beyond either ingredient alone.
Read the full article →
June 16, 2026
TriNutra's US patent protects ThymoQuin and astaxanthin compositions that exhibit greater combined efficacy than the sum of their parts, driven by ThymoQuin's standardized thymoquinone and p-cymene balance.
Read the full article →
October 9, 2025
NutraIngredients USA previews SupplySide Global 2025, highlighting ThymoQuin among standout ingredients on the show floor.
Read the full article →October Issue, 2025
Gene Bruno's feature article examines the cortisol-lowering effects of standardized black seed oil, with ThymoQuin cited as a clinically studied example.
Read the full article →September 26, 2025
WholeFoods Magazine's raw materials roundup includes ThymoQuin among 50+ ingredients worth knowing, spotlighting its standardized thymoquinone content and cortisol-related benefits.
Read the full article →
JOIN THE COMMUNITY
Wellness starts with
what you know